In conversation with... Janet Brown
from Listen to The Lancet Oncology Hosted by The Lancet
Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of Listen to The Lancet Oncology?
This episode is 20 minutes long.
When was this Listen to The Lancet Oncology episode published?
This episode was published on March 1, 2023.
Can I download this Listen to The Lancet Oncology episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.